Candriam S.C.A. Buys 26,144 Shares of IQVIA Holdings Inc. $IQV

Candriam S.C.A. lifted its position in IQVIA Holdings Inc. (NYSE:IQV) by 18.3% during the 2nd quarter, Holdings Channel reports. The firm owned 169,180 shares of the medical research company’s stock after buying an additional 26,144 shares during the quarter. Candriam S.C.A.’s holdings in IQVIA were worth $26,662,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Verdence Capital Advisors LLC bought a new position in IQVIA in the 2nd quarter valued at $3,612,000. Patton Fund Management Inc. acquired a new stake in shares of IQVIA in the second quarter valued at $231,000. Heritage Investors Management Corp raised its holdings in shares of IQVIA by 10.5% in the second quarter. Heritage Investors Management Corp now owns 104,704 shares of the medical research company’s stock valued at $16,500,000 after buying an additional 9,909 shares during the last quarter. Private Advisor Group LLC lifted its position in IQVIA by 11.6% during the 1st quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock worth $958,000 after buying an additional 566 shares in the last quarter. Finally, Nordea Investment Management AB grew its holdings in IQVIA by 41.7% during the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after acquiring an additional 606,391 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the sale, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.60% of the stock is currently owned by company insiders.

IQVIA Stock Performance

Shares of IQVIA stock opened at $223.36 on Friday. The firm has a fifty day moving average of $202.05 and a two-hundred day moving average of $178.04. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The stock has a market capitalization of $38.04 billion, a price-to-earnings ratio of 30.64, a PEG ratio of 2.47 and a beta of 1.34. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $228.12.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same period in the previous year, the firm earned $2.84 earnings per share. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on IQV shares. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. Stifel Nicolaus increased their price target on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Barclays boosted their price objective on shares of IQVIA from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 2nd. JPMorgan Chase & Co. increased their price objective on IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Finally, Truist Financial restated a “buy” rating and set a $265.00 target price (up previously from $235.00) on shares of IQVIA in a research report on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $241.00.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.